UNC79

Summary

UNC79 (unc-79 subunit of NALCN channel complex, HGNC:19966) is a protein-coding gene on chromosome 14q32.12, encoding Protein unc-79 homolog (Q9P2D8). Auxiliary subunit of the NALCN sodium channel complex, a voltage-gated ion channel responsible for the resting Na(+) permeability that controls neuronal excitability.

The NALCN channel is responsible for Na(+) leak currents. The protein encoded by this gene, along with UNC80, is an accessory subunit of the NALCN channel that contributes to the Ca(2+) sensitivity of the channel.

Source: NCBI Gene 57578 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 10
• Clinical variants (ClinVar): 416 total — 8 pathogenic, 6 likely-pathogenic
• MANE Select transcript: NM_001395159

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19966
Approved symbol	UNC79
Name	unc-79 subunit of NALCN channel complex
Location	14q32.12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000133958
Ensembl biotype	protein_coding
OMIM	616884
Entrez	57578

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 retained_intron

ENST00000256339, ENST00000393151, ENST00000553484, ENST00000554549, ENST00000555664, ENST00000621021, ENST00000695012, ENST00000695013

RefSeq mRNA: 3 — MANE Select: NM_001395159 NM_001346218, NM_001395159, NM_020818

CCDS: CCDS91920, CCDS91921, CCDS9911

Canonical transcript exons

ENST00000629588 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 106 present calls, max score 85.99.

FANTOM5 (CAGE): breadth broad, TPM avg 2.7404 / max 161.9060, expressed in 363 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
141178	0.7744	148
141181	0.7342	128
141174	0.3370	142
141177	0.3104	99
141173	0.2499	123
141179	0.2295	84
141180	0.1050	56

Top tissues by expression

120 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	85.99	gold quality
cerebellar cortex	UBERON:0002129	85.68	gold quality
cerebellar hemisphere	UBERON:0002245	85.68	gold quality
cerebellum	UBERON:0002037	85.66	gold quality
superior frontal gyrus	UBERON:0002661	83.45	gold quality
pituitary gland	UBERON:0000007	83.21	gold quality
cortical plate	UBERON:0005343	82.78	gold quality
right frontal lobe	UBERON:0002810	81.29	gold quality
primary visual cortex	UBERON:0002436	81.06	gold quality
adenohypophysis	UBERON:0002196	81.00	gold quality
frontal cortex	UBERON:0001870	80.54	gold quality
islet of Langerhans	UBERON:0000006	80.08	gold quality
Brodmann (1909) area 9	UBERON:0013540	79.94	gold quality
prefrontal cortex	UBERON:0000451	79.87	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	79.19	gold quality
cerebral cortex	UBERON:0000956	78.67	gold quality
brain	UBERON:0000955	78.63	gold quality
ganglionic eminence	UBERON:0004023	78.05	gold quality
anterior cingulate cortex	UBERON:0009835	77.33	gold quality
corpus callosum	UBERON:0002336	77.14	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.99	gold quality
nucleus accumbens	UBERON:0001882	76.71	gold quality
hypothalamus	UBERON:0001898	76.33	gold quality
caudate nucleus	UBERON:0001873	74.58	gold quality
Ammon’s horn	UBERON:0001954	74.28	gold quality
putamen	UBERON:0001874	74.25	gold quality
temporal lobe	UBERON:0001871	74.15	gold quality
amygdala	UBERON:0001876	74.04	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	73.74	gold quality
substantia nigra	UBERON:0002038	71.38	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-75140	yes	159.28
E-ANND-3	no	1.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

58 targeting UNC79, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6798-5P	100.00	65.77	699
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-3121-3P	99.82	71.96	3630

Literature-anchored findings (GeneRIF, showing 4)

• In the Australian GWAS, one SNP achieved genomewide significance for comorbid AD/ND, rs12882384 in KIAA1409 on chromosome 14 (p = 4.86 x 10(-8))). (PMID:20158304)
• UNC80 encodes a large protein that is necessary for the stability and function of NALCN and for bridging NALCN to UNC79 to form a functional complex (PMID:26708753)
• UNC79 variant is associated with neurodevelopmental diseases. (PMID:30167850)
• A new neurodevelopmental disorder linked to heterozygous variants in UNC79. (PMID:37183800)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Unc79	ENSMUSG00000021198
rattus_norvegicus	Unc79	ENSRNOG00000008728
drosophila_melanogaster	unc79	FBGN0038693
caenorhabditis_elegans		WBGENE00006811

Protein

Protein identifiers

Protein unc-79 homolog — Q9P2D8 (reviewed: Q9P2D8)

All UniProt accessions (4): A0A8Q3SHI5, A0A8Q3SHN5, G3V2U4, Q9P2D8

UniProt curated annotations — full annotation on UniProt →

Function. Auxiliary subunit of the NALCN sodium channel complex, a voltage-gated ion channel responsible for the resting Na(+) permeability that controls neuronal excitability. Activated by neuropeptides substance P, neurotensin, and extracellular calcium that regulates neuronal excitability by controlling the sizes of NALCN-dependent sodium-leak current.

Subunit / interactions. NALCN complex consists of NALCN and auxiliary subunits, UNC79, UNC80 and NACL1. These auxiliary subunits are essential for the NALCN channel function. UNC80 bridges NALCN to UNC79.

Subcellular location. Cell membrane.

Similarity. Belongs to the unc-79 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9P2D8-1	1	yes
Q9P2D8-2	2
Q9P2D8-3	3

RefSeq proteins (3): NP_001333147, NP_001382088, NP_065869 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016024	ARM-type_fold	Homologous_superfamily
IPR024855	UNC79	Family

Pfam: PF14776

UniProt features (121 total): helix 87, region of interest 6, strand 6, compositionally biased region 5, sequence variant 4, turn 4, transmembrane region 2, modified residue 2, splice variant 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
7SX3	ELECTRON MICROSCOPY	3.1
7SX4	ELECTRON MICROSCOPY	3.5
7WJI	ELECTRON MICROSCOPY	4.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P2D8-F1	63.95	0.04

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 754, 758

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2672351	Stimuli-sensing channels

MSigDB gene sets: 106 (showing top): MODULE_255, GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, TTTGTAG_MIR520D, MODULE_317, GOBP_MONOATOMIC_CATION_TRANSPORT, MODULE_171, TGIF_01, GOBP_REGULATION_OF_ACTION_POTENTIAL, GOBP_REGULATION_OF_NERVOUS_SYSTEM_PROCESS, GOBP_REGULATION_OF_SYSTEM_PROCESS, AACTTT_UNKNOWN, CTTTGTA_MIR524, GOBP_REGULATION_OF_TRANSMISSION_OF_NERVE_IMPULSE, GOBP_NEURONAL_ACTION_POTENTIAL, chr14q32

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Ion channel transport	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1326 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UNC79	UNC80	Q8N2C7	994
UNC79	NALCN	Q8IZF0	962
UNC79	NALF1	B1AL88	821
UNC79	C2CD4A	Q8NCU7	702
UNC79	NALF2	O75949	577
UNC79	CEACAM4	O75871	575
UNC79	UNC119	Q13432	539
UNC79	GK5	Q6ZS86	488
UNC79	STOML1	Q9UBI4	476
UNC79	SPIDR	Q14159	456
UNC79	DYM	Q7RTS9	456
UNC79	BTBD7	Q9P203	449
UNC79	UBR7	Q8N806	444
UNC79	TMEM117	Q9H0C3	438
UNC79	STRBP	Q96SI9	426

IntAct

10 interactions, top by confidence:

A	B	Type	Score
CALM1	NALF1	psi-mi:“MI:0915”(physical association)	0.570
UNC79	HMGA1	psi-mi:“MI:0915”(physical association)	0.400
UNC79	H2AC4	psi-mi:“MI:0915”(physical association)	0.400
IGHA1	PLG	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350

BioGRID (13): UNC79 (Affinity Capture-MS), UNC79 (Affinity Capture-MS), UNC79 (Affinity Capture-MS), UNC79 (Affinity Capture-MS), UNC79 (Proximity Label-MS), UNC79 (Proximity Label-MS), UNC79 (Affinity Capture-MS), PSMA8 (Cross-Linking-MS (XL-MS)), UNC79 (Cross-Linking-MS (XL-MS)), UNC79 (Co-fractionation), UNC79 (Proximity Label-MS), UNC79 (Affinity Capture-RNA), UNC79 (Reconstituted Complex)

ESM2 similar proteins: A0JMW6, A1A535, A1A5P5, A1L1L2, A1L2I9, A2BID5, A4FV45, A7Z033, F1QN74, P56695, Q08CY4, Q0KK59, Q14D04, Q2PW47, Q3UHQ6, Q568Z0, Q5FWU8, Q5JWR5, Q5PQS3, Q5SPP5, Q5U249, Q642P2, Q68F70, Q68Y81, Q6DRL5, Q6GPP1, Q6GQ26, Q6IV68, Q6NUQ4, Q6PI53, Q7SYB2, Q7Z3E5, Q7ZYV9, Q80V62, Q80X82, Q8BL99, Q8BM55, Q8CIM8, Q8JGR7, Q8K1H7

Diamond homologs: P42173, Q0KK59, Q9P2D8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
UNC80	“up-regulates activity”	UNC79	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

416 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	8
Likely pathogenic	6
Uncertain significance	335
Likely benign	43
Benign	4

Top pathogenic / likely-pathogenic (14)

Variant ID	HGVS	Classification
3370626	NM_001395159.1(UNC79):c.6973C>T (p.Arg2325Ter)	Pathogenic
3813609	NM_001395159.1(UNC79):c.1879del (p.Glu627fs)	Pathogenic
3813610	NM_001395159.1(UNC79):c.4027C>T (p.Gln1343Ter)	Pathogenic
3901859	NM_001395159.1(UNC79):c.4658dup (p.His1554fs)	Pathogenic
3977809	NM_001395159.1(UNC79):c.751A>T (p.Lys251Ter)	Pathogenic
4278632	NM_001395159.1(UNC79):c.2601C>A (p.Cys867Ter)	Pathogenic
4531490	NM_001395159.1(UNC79):c.7695_7697delinsT (p.Asn2566fs)	Pathogenic
4683117	NM_001395159.1(UNC79):c.5542dup (p.Glu1848fs)	Pathogenic
4088188	NM_001395159.1(UNC79):c.2236C>T (p.Arg746Ter)	Likely pathogenic
4196313	NM_001395159.1(UNC79):c.7089del (p.Asp2363fs)	Likely pathogenic
4292289	NM_001395159.1(UNC79):c.4107+1del	Likely pathogenic
4528309	NM_001395159.1(UNC79):c.6955C>T (p.Arg2319Ter)	Likely pathogenic
4538265	NM_001395159.1(UNC79):c.6047_6048dup (p.Glu2017fs)	Likely pathogenic
4730260	NM_001395159.1(UNC79):c.3191-2A>C	Likely pathogenic

SpliceAI

9462 predictions. Top by Δscore:

Variant	Effect	Δscore
14:93333460:A:T	donor_gain	1.0000
14:93351145:G:GT	donor_gain	1.0000
14:93455657:T:TA	donor_gain	1.0000
14:93455658:A:AA	donor_gain	1.0000
14:93467669:A:AG	acceptor_gain	1.0000
14:93467670:G:GG	acceptor_gain	1.0000
14:93467670:GTT:G	acceptor_gain	1.0000
14:93477554:GTAG:G	acceptor_loss	1.0000
14:93477555:TA:T	acceptor_loss	1.0000
14:93477556:A:AG	acceptor_gain	1.0000
14:93477557:G:GA	acceptor_gain	1.0000
14:93477557:G:GC	acceptor_loss	1.0000
14:93477557:GAT:G	acceptor_gain	1.0000
14:93477722:GCTA:G	donor_gain	1.0000
14:93477725:ATATG:A	donor_loss	1.0000
14:93477727:ATGT:A	donor_loss	1.0000
14:93477728:TG:T	donor_loss	1.0000
14:93477729:G:C	donor_loss	1.0000
14:93477729:G:GG	donor_gain	1.0000
14:93477730:TAA:T	donor_loss	1.0000
14:93487661:A:AG	acceptor_gain	1.0000
14:93487662:G:GG	acceptor_gain	1.0000
14:93496467:G:GG	donor_gain	1.0000
14:93528645:GG:G	donor_gain	1.0000
14:93528646:GG:G	donor_gain	1.0000
14:93537987:A:AG	acceptor_gain	1.0000
14:93537988:G:GA	acceptor_gain	1.0000
14:93537988:GAACT:G	acceptor_gain	1.0000
14:93538214:ATCAG:A	donor_gain	1.0000
14:93538216:CAG:C	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000011634 (14:93352653 C>A), RS1000020735 (14:93556448 A>T), RS1000030835 (14:93639820 T>A), RS1000034822 (14:93462804 A>C,G,T), RS1000036302 (14:93691186 C>A,T), RS1000051356 (14:93629172 C>A), RS1000065416 (14:93508630 A>T), RS1000084545 (14:93500010 G>A), RS1000093750 (14:93360004 A>G), RS1000102198 (14:93564290 A>G), RS1000106999 (14:93452520 C>G), RS1000109486 (14:93692656 A>G), RS1000109768 (14:93360150 G>A,T), RS1000110496 (14:93407438 T>G), RS1000111583 (14:93669622 C>A,G)

Disease associations

OMIM: gene MIM:616884 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Strong	Autosomal dominant
neurodevelopmental disorder	Strong	Autosomal dominant

Mondo (5): autism spectrum disorder (MONDO:0005258), prostate cancer (MONDO:0008315), neurodevelopmental disorder (MONDO:0700092), epilepsy (MONDO:0005027), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (2): Familial prostate cancer (Orphanet:1331), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST003980_5	Sleep duration	1.000000e-07
GCST004904_2	Body mass index	2.000000e-09
GCST005830_138	Hand grip strength	2.000000e-09
GCST005951_7	Body mass index	4.000000e-08
GCST007519_2	Adult asthma	3.000000e-06
GCST009391_1242	Metabolite levels	7.000000e-06
GCST010774_6	Essential hypertension (time to event)	1.000000e-07
GCST010988_544	Adult body size	1.000000e-20
GCST90000047_251	Age at first sexual intercourse	2.000000e-11
GCST90000514_23	Gastroesophageal reflux disease	8.000000e-10

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0006941	grip strength measurement
EFO:0010422	triacylglycerol 54:4 measurement
EFO:0004918	age at diagnosis
EFO:0009749	age at first sexual intercourse measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D004827	Epilepsy	C10.228.140.490
D065886	Neurodevelopmental Disorders	F03.625
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases methylation	2
bisphenol A	affects cotreatment, increases methylation	1
perfluorooctanoic acid	increases expression	1
tobacco tar	decreases reaction, increases expression	1
benzo(e)pyrene	increases methylation	1
diallyl disulfide	decreases reaction, increases expression	1
cupric chloride	decreases expression	1
allyl sulfide	decreases reaction, increases expression	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Vorinostat	affects cotreatment, decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Methapyrilene	increases methylation	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	increases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

500 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder